Tests a heart catheter for monitoring in severe heart failure shock
Compares heart monitoring with a catheter in adults with shock from weakened heart pumping.
Plain-language title generated from the registry record
Registry title: Pulmonary Artery Catheterization and Carvedilol Early Initiation in Cardiogenic SHOCK Due to HFrEF
Key facts
- Where
- Seoul, South KoreaSee the site
Where in South Korea
- Asan Medical CenterSeoul, South KoreaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Min-Seok Kim
- Trial code
- NCT06078436
- Record updated
- 5 January 2024
- Original description
This study aims to compare the impact of hemodynamic monitoring using pulmonary artery catheter (PAC) on survival and inotropic agent reduction in patients with cardiogenic shock caused by heart failure with reduced ejection fraction (HFrEF). The investigators also intend to compare the difference in long-term survival rates among patients who have recovered from cardiogenic shock due to HFrEF, based on the timing of initiation of beta-blocker treatment.Read full original descriptionShow less
Pulmonary Artery Catheterization and Carvedilol Early Initiation in Cardiogenic SHOCK Caused by Heart Failure With Reduced Ejection Fraction
This study aims to compare the impact of hemodynamic monitoring using pulmonary artery catheter (PAC) on survival and inotropic agent reduction in patients with cardiogenic shock caused by heart failure with reduced ejection fraction (HFrEF). The investigators also intend to compare the difference in long-term survival rates among patients who have recovered from cardiogenic shock due to HFrEF, based on the timing of initiation of beta-blocker treatment.
Inclusion: Adults age 19 and above ( no age limit for elderly ); Patients with cardiogenic shock requiring intensive care monitoring in ICU; Patients eligible for oral medication administration; Patients who have provided research participation consent through a written informed consent form.
Exclusion: Patients currently undergoing de-sensitization therapy; Patients with acute coronary syndrome; Patients with severe valvular heart disease requiring emergent percutaneous procedures or surgery; Known hypersensitivity to beta-blockers; Patients with a history of bronchospasm or asthma; Patients with sick sinus syndrome, including sinoatrial block; Unwilling or unable to obtain informed consent by the participant or substitute decision maker; Patients with mechanical circulatory support at the time of screening; Patients with bradycardia or second or third-degree atrioventricular block; Patients with untreated pheochromocytoma; Patients who are currently pregnant, postpartum period within 30 days or breast-feeding.